SLC5A2 and chronic kidney disease: Finally, sodium-glucose cotransporter-2 (SGLT2) inhibitors, now widely used in diabetic and non-diabetic CKD, consistently reduce circulating oxidative and inflammatory markers alongside their established renoprotective effects, suggesting that redox modulation contributes to their clinical efficacy [28].